Matisse Pharmaceuticals, a clinical-stage company based in Geelan, the Netherlands, has announced securing €3.6M in a fresh funding round. This investment, contributed by Brightlands Venture Partners, private investment companies, informal investors, and the management team, will support Matisse in its preparation for a large-scale phase II study in sepsis patients.
